<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819975</url>
  </required_header>
  <id_info>
    <org_study_id>CERN-PPL (5B) LSM</org_study_id>
    <nct_id>NCT00819975</nct_id>
  </id_info>
  <brief_title>Differential Effects of Milk Proteins on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes</brief_title>
  <official_title>Differential Effects of Milk Proteins on Postprandial Lipemia in Response to a Fat-Rich Meal in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Danish Obesity Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordic Centre of Excellence</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enhanced and prolonged postprandial triglyceride responses involve increased cardiovascular
      risk in type 2 diabetes. It has been demonstrated that dietary fat and carbohydrates
      profoundly influence postprandial hypertriglyceridemia in type 2 diabetes, whereas little
      information exists about the effect of proteins.

      The purpose of this study is to compare the effects of the milk proteins casein, Whey
      Isolate, Whey Hydrolysate, and Alphalact-Albumin on postprandial lipid and incretin responses
      to a high-fat meal in type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">May 2008</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Triglyceride levels</measure>
    <time_frame>0h- 2h- 4h- 6h- 7h- 8h postprandial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incretin levels</measure>
    <time_frame>0h- 0.5h- 1h- 2h- 4h- 6h- 8h postprandial</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Postprandial Lipemia</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Casein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Whey Isolate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Whey Hydrolysate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alphalact-Albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Casein</intervention_name>
    <arm_group_label>Casein</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whey Isolate</intervention_name>
    <arm_group_label>Whey Isolate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Whey Hydrolysate</intervention_name>
    <arm_group_label>Whey Hydrolysate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alphalact-Albumin</intervention_name>
    <arm_group_label>Alphalact-Albumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes

        Exclusion Criteria:

          -  Liver-, Kidney- and/or Heart Disease

          -  Serious Hypertension (160/110 mmHg)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kjeld Hermansen, Professor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology and Metabolism</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Nutrition</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2009</study_first_posted>
  <last_update_submitted>January 8, 2009</last_update_submitted>
  <last_update_submitted_qc>January 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kjeld Hermansen, Professor, Chief Physician, MD, Dr.Med.Sci</name_title>
    <organization>Department of Endocrinology and Metabolism, Aarhus University Hospital</organization>
  </responsible_party>
  <keyword>Casein</keyword>
  <keyword>Whey</keyword>
  <keyword>postprandial</keyword>
  <keyword>Triglyceride</keyword>
  <keyword>Free fatty acids</keyword>
  <keyword>Retinyl palmitate</keyword>
  <keyword>Incretins</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caseins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

